



Introduction and Update

William M. Burns

CEO Division Roche Pharmaceuticals



Background Briefing on Tamiflu

10.30 – 10.45 Introduction and issues update

William M. Burns, CEO Pharma Division, Roche

10.45 – 11.05 Update on Pandemic potential of H5N1

John Oxford, Professor of Virology, Queen Mary's University of London, United Kingdom

11.05 – 11.35 Tamiflu and Roche Pandemic Strategy

Eugene Tierney, Global Head of Virology and Transplantation, Roche

David Reddy, Pandemic Task Force Leader, Roche

11.35 – 12.00 The challenges of Tamiflu Manufacture

Jan van Koeveringe, Head of Pharmaceutical Global Technical Operations, Roche

12.00 – 12.30 Q&A

13.30 – 16.30 Tour of the Manufacturing Facilities



Topics covered

- Tamiflu – the last 10 years
- Spread of H5N1
- Resistance
- Production
- Out licensing/Collaboration
- Price
- Future research
 - Trials
 - Surveillance
 - Diagnostics
- Gilead



Conclusions

- Patients' needs are our top priority
- Speed, capacity and quality of production are key
- Roche is working with Governments and the WHO on pandemic planning
 - Pandemic preparedness is Tamiflu and much more
- Roche is more than just Tamiflu. We remain fully focused on all key therapy areas and diagnostics